Clinical Trials
9
Active:0
Completed:6
Trial Phases
4 Phases
Early Phase 1:1
Phase 1:3
Phase 2:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (37.5%)Phase 2
3 (37.5%)Early Phase 1
1 (12.5%)Not Applicable
1 (12.5%)A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
Phase 2
Not yet recruiting
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Drug: CGB-500 Ointment with 1% tofacitinib
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT06923228
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Phase 2
Recruiting
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Drug: CGB-500 with 0.5% tofacitinibDrug: CGB-500 Ointment with 1% tofacitinibDrug: Vehicle (placebo)
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT06810050
- Locations
- 🇺🇸
Center for Dermatology Clinical Research Inc., Fremont, California, United States
🇺🇸Ablon Skin Institute and Research Center, Manhattan Beach, California, United States
🇺🇸TCR Medical Corporation, San Diego, California, United States
Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Other: placebo ointment
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05487963
- Locations
- 🇬🇪
Kani Clinic, Tbilisi, Georgia
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
- Conditions
- Fungal InfectionOnychomycosisTinea Unguium
- Interventions
- Drug: CGB-400 Topical Gel
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05202366
- Locations
- 🇺🇸
John Peter Smith Hospital, Fort Worth, Texas, United States
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT04886739
- Locations
- 🇺🇸
Cage Bio Investigative Site 1, Fremont, California, United States
- Prev
- 1
- 2
- Next
News
No news found